Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

In this study, PDLLA treatment in middle-aged mice was observed to enhance hair growth by increasing macrophage M2 polarization and hair follicle stem cell proliferation, potentially rejuvenating the skin's microenvironment and offering a novel approach for age-related hair loss.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This study observed that atopic dermatitis severity was associated with higher eosinophil counts and FLG variants, suggesting distinct endotypes that may require tailored treatment approaches.

This study found that the distribution of desmogleins is associated with specific types of keratinization and hair anchorage, as well as hypotrichosis.

This review found that the DLQI is widely used as a benchmark in the development and validation of dermatology quality-of-life measures.

GLABRA2 gene controls root-hair growth by regulating phospholipid signaling.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.

DMG-Na may help reduce hair loss and improve hair growth, but more research is needed.

This study found that PDLLA filler treatment may help combat age-related hair thinning by reducing oxidative stress and enhancing hair follicle function in both cell and animal models.

This case report describes a 12-year-old boy with severe skin scaling due to novel compound heterozygous null truncation mutations in the TGM1 gene, resulting in loss of transglutaminase 1 activity.

GLABRA2 represses root hair formation by inhibiting a specific gene.

In this study, 2-deoxy D-glucose did not prevent the progression of alopecia areata or promote hair regrowth in a mouse model despite its efficacy in other autoimmune conditions.

This study suggests that valine and certain VLDL subfractions are positively associated with androgenetic alopecia risk, while reverse analysis showed AGA does not affect these metabolites.

In this case report, a rare instance of Graham–Little–Piccardi–Lassueur syndrome coexisting with linear lichen planus was identified in a 35-year-old male, highlighting the condition's rarity in males, with dermoscopy aiding diagnosis through distinctive scalp and trunk lesion features.

This study found that low-level laser therapy increased the expression of proteins in dermal papilla tissues, suggesting it promotes hair growth in male androgenetic alopecia patients.

This study found that gels containing glycyrrhizic acid and aqueous Glycyrrhiza glabra extract significantly reduced underarm hair growth in terms of area, thickness, length, and number compared to their gel bases.

This study found that pretreating concentrated growth factor with a 640 nm laser increased CD34+ stem cell activation and improved hair growth outcomes in androgenetic alopecia patients compared to non-pretreated CGF.

PGD2 stops hair growth and is higher in bald men with AGA.

This study reported that an injectable hydrogel based on platelet-rich plasma and laponite improved wound healing in diabetic and normal rats by enhancing angiogenesis and macrophage polarization.

In this randomized, double-blind trial, researchers observed that low-level laser therapy led to significantly greater hair regrowth on treated areas compared to a sham treatment in patients with androgenetic alopecia over 24 weeks, suggesting it as a potentially effective and safe option.

This study reports two cases of follicular lichen planus, suggesting that GLPLS and LPP may be variants of this condition based on clinical and immunofluorescent findings.

A woman with X-linked chronic granulomatous disease developed lupus-like skin lesions, improved with treatment, suggesting a unique skin condition in carriers.

Higher fluence low-level laser therapy effectively promotes hair growth in androgenetic alopecia, with varying effects based on sex.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

In this pilot study, treatment with lyophilized platelet derived growth factors showed improvement in women with androgenetic alopecia, suggesting it may be a promising new therapy.

This study found that low-level light therapy significantly increased hair density and diameter in androgenetic alopecia patients compared to a sham device, suggesting it could be an effective treatment option.